A strong result from Eli Lilly overnight came amid a 2.3% surge in the S&P 500, the best day for the index since 2022. Eli Lilly raised sales and profit guidance for the year after a strong performance by its diabetes and weight loss drugs Mounjaro and Zepbound.

Most of the US companies we’re watching have now reported and the frequency of results now slows down. Stocks of interest still yet to report include Home Depot (13 August), Cisco (14 August), Walmart (15 August), Palo Alto Networks (19 August) and NVIDIA (28 August).

Eli Lilly

In contrast to yesterday’s lacklustre result from Novo Nordisk, Eli Lilly knocked it out of the park overnight with a strong Q2 result and an increase in its full year guidance. Quarterly sales of the Zepbound weight-loss drug passed $1 billion for the first time. Supply of both Mounjaro and Zepbound increased during Q2 and Lilly said it was able to backfill orders and increase stocks at wholesalers. Lilly now expects adjusted profit of $45.4-46.6 billion in 2024, up from $42.4-43.6 billion. Some investors have speculated that the strong performance of Eli Lilly in the period means it is outmaneuvering Novo Nordisk in the push to increase manufacturing capacity.

Key August reporting results for Eli Lilly

The roundup

Almost all US companies have now released their quarterly earnings. The median EPS beat has been 4.2% and the median yoy EPS growth 9.7%.

      
Download full report
      

Disclaimer: The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.

News & Insights

This edition of the Month Ahead presents ideas from three areas of focus for Morgans: domestic equities, ETFs and global equities. We take a look at the opportunities presented by Light & Wonder, the Firetrail Australian Small Companies Fund and Eli Lilly.
Read full article
We recommend investors start making sense of AI by considering stock opportunities in three distinct areas: artificial intelligence, digital infrastructure, and data networks.
Read full article
Most results were thereabouts against expectations which saw the sector perform broadly in line with the index. Top picks are ALQ and CVL.
Read full article

News & Insights

A strong result from Eli Lilly came amid a 2.3% surge in the S&P 500, the best day for the index since 2022. Eli Lilly raised sales and profit guidance for the year after a strong performance by its diabetes and weight loss drugs Mounjaro and Zepbound.
Find out more